Clinical Trial SuccessMiv-cel met the primary and all secondary endpoints in stiff person syndrome (SPS), which the KOL characterized as remarkable.
Market StrategyKyverna is poised to have the first FDA-approved CAR-T for the treatment of an autoimmune disease.
Regulatory ProgressFrequent and consistent meetings with the FDA suggest a reduced regulatory risk for the company.